OTC: VYST

Vystar Corp

CIK 0001308027 · SIC 3060 · Fabricated Rubber Products, NEC

Micro Revenue $55K Assets $910K as of Nov 21, 2026

Vystar Corporation (“Vystar”, the “Company”, “we,” “us,” or “our”) is based in Worcester, Massachusetts. Vystar is the owner and manufacturer of multiple brands of eco-friendly products for the home, office and medical sectors. The Company is focused on three main brands Vytex, RXAIR, and Fluid… About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.

10-Q Filed Nov 20, 2026 · Period ending Sep 30, 2026

Summary not yet generated.

10-Q Filed Aug 13, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

Partner

Trade VYST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Aug 6, 2026 · Period ending Aug 4, 2026

Summary not yet generated.

10-K Filed Apr 15, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-K Filed Apr 14, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

8-K Filed Feb 5, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

8-K Filed Jul 26, 2024 · Period ending Jul 22, 2024

Summary not yet generated.

10-Q/A Filed Dec 4, 2020 · Period ending Sep 30, 2020

Summary not yet generated.

10-K/A Filed Mar 29, 2018 · Period ending Dec 31, 2017

Summary not yet generated.

Latest financial statements

From 10-Q filed Nov 20, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations (Unaudited)

Description Three months ended September 30, 2026 Three months ended September 30, 2025 Nine months ended September 30, 2026 Nine months ended September 30, 2025
Revenue 60,840 20,385 74,754 44,657
Cost of revenue (2,761) 5,020 (407) 18,603
Gross profit 63,601 15,365 75,161 26,054
Operating expenses:
Salaries and commissions 25,033 647 30,754 647
Share-based compensation 42,413 199,097 317,225 559,287
Professional fees 39,061 24,174 143,470 176,599
Advertising 1,050 1,825 3,500 3,392
Rent 11,822 10,464 34,668 31,434
Service charges 294 1,137 1,261 3,360
Depreciation and amortization 4,008 15,484 24,163 52,738
Other operating 12,462 9,513 36,399 50,945
Total operating expenses 136,143 262,341 591,440 878,402
Loss from operations (72,542) (246,976) (516,279) (852,348)
Other income (expense):
Interest expense (30,498) (24,411) (253,294) (303,943)
Loss on settlement of debt, net - - 76,725 (79,846)
Other income 11,508 - 11,508 -
Total other expense, net (18,990) (24,411) (165,061) (383,789)
Net loss from continuing operations (91,532) (271,387) (681,340) (1,236,137)
Discontinued operations:
Loss from operations - - (456) (456)
Net loss (91,532) (271,387) (681,796) (1,236,593)
Net loss attributable to noncontrolling interest - - 192 192
Net loss attributable to Vystar (91,532) (271,387) (681,604) (1,236,401)
Basic and diluted loss per share:
Net loss from continuing operations (0.00) (0.01) (0.03) (0.07)
Net loss from discontinued operations (0.00) (0.00) (0.00) (0.00)
Net loss attributable to noncontrolling interest (0.00) (0.00) (0.00) (0.00)
Net loss attributable to common shareholders (0.00) (0.01) (0.03) (0.07)
Basic and diluted weighted average number of common shares outstanding 25,373,908 20,203,472 24,874,790 18,459,356

Condensed Consolidated Balance Sheets

Description September 30, 2026 (Unaudited) December 31, 2025
ASSETS
Current assets:
Cash 65,784 4,454
Accounts receivable 385 338
Inventories, net 54,711 58,912
Prepaid expenses and other 311,881 304,719
Assets of discontinued operations 5,145 5,601
Total current assets 437,906 374,024
Property and equipment, net - 12,139
Other assets:
Investment in joint venture 417,420 -
Intangible assets, net 54,263 66,287
Total other assets 471,683 66,287
Total assets 909,589 452,450
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable 1,470,593 1,353,412
Accrued expenses 456,233 428,924
Related party stock subscription payable 2,881,350 2,566,036
Stock subscription payable, net of related party 568,648 558,648
Shareholder, convertible and contingently convertible notes payable
and accrued interest current maturities 32,604 31,434
Related party debt current maturities, net of debt discount 1,135,770 971,447
Derivative liabilities 469,314 423,632
Unearned revenue 44,337 44,337
Related party advances 77,460 79,460
Liabilities of discontinued operations 530,863 530,863
Total current liabilities 7,667,172 6,988,193
Stockholders’ deficit:
Convertible preferred stock series class A, $0.0001 par value 15,000,000 shares authorized; 8,698 shares issued and outstanding at September 30, 2026 and December 31, 2025 (liquidation preference of $203,000 and $196,000 at September 30, 2026 and December 31, 2025, respectively) 1 1
Convertible preferred stock series B, $0.0001 par value 2,500,000 shares authorized; 336,645 and 321,083 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively, (liquidation preference of $3,297,000 and $3,020,000 at September 30, 2026 and December 31, 2025, respectively) 34 32
Convertible preferred stock series C, $0.0001 par value 2,500,000 shares authorized; 1,917,973 shares issued and outstanding at September 30, 2026 and December 31, 2025 (liquidation preference of $7,110,000 and $6,736,000 at September 30, 2026 and December 31, 2025, respectively) 192 192
Common stock, $0.0001 par value, 1,500,000,000 shares authorized; 27,009,631 and 24,621,394 shares issued at September 30, 2026 and December 31, 2025, respectively, and 27,009,331 and 24,621,094 shares outstanding at September 30, 2026 and December 31, 2025, respectively 2,701 2,462
Additional paid-in capital 55,336,477 54,876,762
Accumulated deficit (62,066,487) (61,384,883)
Common stock in treasury, at cost; 300 shares (30) (30)
Total Vystar stockholders’ deficit (6,727,112) (6,505,464)
Noncontrolling interest (30,471) (30,279)
Total stockholders’ deficit (6,757,583) (6,535,743)
Total liabilities and stockholders’ deficit 909,589 452,450

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Nine months ended September 30, 2026 Nine months ended September 30, 2025
Cash flows from operating activities:
Net loss (681,796) (1,236,593)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation 317,225 559,287
Depreciation 12,139 32,094
Amortization of intangible assets 12,024 20,644
Amortization of debt discount 163,092 231,228
Expenses paid directly by related party debt 16,637 106,533
(Gain) loss on settlement of debt, net (76,725) 79,846
(Increase) decrease in assets:
Accounts receivable (47) 15,050
Inventories 4,201 9,596
Prepaid expenses and other (7,162) 604
Increase (decrease) in liabilities:
Accounts payable (6,094) (9,229)
Accrued expenses and interest payable 96,715 24,677
Net cash used in operating activities (149,791) (166,263)
Cash flows from investing activities:
Investment in joint venture (50,000) -
Cash flows from financing activities:
Proceeds from related party advances 6,500 -
Repayment of related party term debt (37,960) (41,527)
Repayment of related party advances (8,500) (8,794)
Advances from stock subscription payable 10,000 208,636
Proceeds from issuance of preferred stock 290,625 -
Proceeds from issuance of common stock - 16,364
Net cash provided by financing activities 260,665 174,679
Net increase in cash 60,874 8,416
Cash beginning of period 9,664 13,378
Less: cash of discontinued operations (4,754) (5,210)
Cash of continuing operations end of period 65,784 16,584
Cash paid during the period for:
Interest 20,796 63,983
Taxes 456 412
Non-cash transactions:
Deferred liability for investment in joint venture 200,000 -
Preferred stock issued for investment in joint venture 167,420 -
Derivatives issued as a debt discount 45,521 54,333
Common stock issued for accrued share-based compensation 1,911 62,198
Common stock issued for settlement of debt and accrued interest - 202,796
Stock subscription payable issued for settlement of debt and accrued interest, net - 243,636

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About Vystar Corp

Source: Item 1 (Business) from the 10-K filed April 15, 2026. Description as filed by the company with the SEC.

ITEM
1.
BUSINESS

Overview

Vystar
Corporation (“Vystar”, the “Company”, “we,” “us,” or “our”) is based in Worcester,
Massachusetts. Vystar is the owner and manufacturer of multiple brands of eco-friendly products for the home, office and medical sectors.
The Company is focused on three main brands Vytex, RXAIR, and Fluid Energy Conversion (FEC). Vystar had a majority ownership in
Murida Furniture Co., Inc. dba Rotmans Furniture (“Rotmans”), formerly one of the largest independent furniture retailers
in the U.S.

All
activities of Rotmans have been included in discontinued operations.

VYTEX

Vystar
is the creator and exclusive owner of the innovative technology to produce Vytex® Natural Rubber Latex (“NRL”). Our global
multi-patented technology reduces antigenic and total protein in natural rubber latex products to virtually undetectable levels. Vytex
NRL, our “ultra-low protein” natural rubber latex has been introduced throughout the worldwide marketplace that uses NRL
or latex substitutes as a raw material for end products. Natural rubber latex or latex substitutes are used in an extensive range of
products including balloons, foams, textiles, adhesives, carpet, paints, coatings, protective equipment, sporting equipment, and especially
health care products like surgical and exam gloves and condoms.

Vystar
has expanded Vytex into the consumer arena with an introduction into the bedding category, aligning with key foam manufacturers to create
mattresses, mattress toppers and pillows. Through this effort, Vystar can bring the benefits of great sleep and a more natural product
to the public.

Read full description ↓

RXAIR

Vystar
is also bringing peace of mind to consumers in the clean-air space. RxAir is the manufacturer of the finest air purification system in
the world and an innovative developer, manufacturer and distributor of bio technology products targeting the rapidly growing Indoor Air
Quality (“IAQ”) industry sector. RxAir’s products include the RxAir purification system for the home as well as one
of the world’s finest lines of hospital-grade HEPA filtration products. All of our products are FDA certified as Class II medical
devices and kill germs viruses and bacteria.

FEC

FEC
has taken a position as a global green energy company with a multitude of new technologies including an array of patented, and soon-to-be
patented, technology destined to change energy production and energy usage in many arenas. Our independent research and development has
focused on product solutions that harness stable vortex effects, cavitation and other unique fluid flow phenomena to move energy application
into new chapters. Our main thrust is currently in water but other applications such as those in combustion are already being positioned
as key concepts in those fields. For over 50 years, FEC’s chief scientist has developed and patented many successful inventions,
both nationally and internationally, involving fluid mechanics, fluidics, thermodynamics and related physics. His experience has created
a revolutionary extension of fluidic science that has led to patented products that are cost effective to manufacture, simple to understand,
and they deliver an outstanding performance. Most of our technology does not require complicated processes or sophisticated electronics,
making us truly unique.

3

Company
Background

In
May of 2018, Vystar acquired substantially all of the assets of UV Flu Technologies, Inc. (formerly traded on the OTC under the ticker
UVFT), whose patented ViraTech™ UV light air purification technology destroys greater than 99% of airborne bacteria, viruses and
other microorganisms and virtually eliminates concentrations of odors and volatile organic compounds (“VOCs”) and created
the RxAir division.

The
RxAir product line includes:

●
RXair™
Residential Filterless Air Purifier

●
RX400
™ U.S. Food and Drug Administration (“FDA”) cleared Class II Filterless Air Purifier

●
RX3000™
Commercial FDA cleared Class II Air Purifier (not currently in production)

RxAir
promotes a healthy lifestyle improving the quality of life of each and every customer. Independently tested by the U.S. Environmental
Protection Agency (“EPA”) and FDA-certified laboratories, the RxAir has been proven to destroy greater than 99% of bacteria
and viruses and reduce concentrations of odors and VOCs. The RxAir uses high-intensity germicidal UV lamps that destroy bacteria and
viruses instead of just trapping them, setting it apart from ordinary air filtration units. RxAir units are sold online at www.RxAir.com
and are available through multiple third-party distributors. RxAir® and ViraTech ® are registered trademarks of Vystar
Corporation.

Vystar
is the exclusive creator of Vytex Natural Rubber Latex (“NRL”), a multi-patented, all-natural, raw material that contains
significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100%
renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a
broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices
and natural rubber latex foam mattresses, toppers, and pillows.

In
April of 2018, Vystar acquired the assets of NHS Holdings, LLC (“NHS”) to move into direct product offerings made from Vytex®
latex. NHS was the exclusive U.S. distributor of Vystar’s Vytex® natural rubber latex foam to manufacturers for use in over
200 home furnishings products, including mattresses, toppers, pillows and upholstery, sold through multiple channels.

In
May of 2019, Vystar acquired the assets of Fluid Energy Conversion Inc. (“FEC”), primarily consisting of its patent on the
Hughes Reactor, which has the ability to control, enhance, and focus energy in flowing liquids and gases. Vystar intends to use this
technology to enhance the effectiveness of Vystar’s RxAir purification system to destroy airborne pathogens while decreasing the
cost and size of Vystar’s RxAir units.

In
July of 2019, Vystar acquired 58% of the outstanding shares of common stock of Murida Furniture Co., Inc. dba Rotmans Furniture (“Rotmans”),
formerly one of the largest independent furniture retailers in the U.S. Rotmans sold a broad line of residential furniture and decorative
accessories and served customers throughout the New England region. The acquisition enabled Vystar to capitalize on the infrastructure
already in place at Rotmans for accounting, retail sales facilities and staff, customer service, warehousing, and delivery. Rotmans closed
its showroom and discontinued its operations at the end of 2022.

4

In
December of 2020, Vystar selected Corrie MacColl Limited, a subsidiary of global natural rubber supply chain manager Halcyon Agri, as
its exclusive global partner for all aspects of product market development and distribution of patented Vytex deproteinized latex.

Competition

RxAir

The
residential air purification market is a highly fragmented competitive business. Vystar competes with a large number of companies on
many factors including price, quality, innovation, reputation, distribution and promotion.

Natural
Rubber Latex

Synthetic
raw materials such as ethylene, propylene, styrene and butadiene compete with NRL. Currently, it is estimated that NRL processors have
lost one-half of the overall latex market to synthetic latex. Despite the switch to non-latex alternatives, it is estimated that almost
70% of exam gloves and nearly 80% of surgical gloves used in U.S. hospitals are still made with NRL.

Intellectual
Property

Vystar
currently holds a portfolio of patents and trademarks in the U.S. and other various foreign countries. No assurance can be given that
such patent and trademark protection will provide substantial protection from competition. We are committed to aggressively challenging
any infringements of our patents and/or trademarks.

Government
Regulation

We
are not subject to direct governmental regulation other than the laws and regulations generally applicable to businesses in the domestic
and foreign jurisdictions in which we operate.

Our
RxAir400 product was cleared by the FDA as a Class II medical device in November 2008. FDA clearance to sell our product as a Class II
medical device provides invaluable credibility in the marketplace. By granting a listing, the FDA indicates it has reviewed all aspects
of a product, including efficacy of the technology, independent test results and product safety to ensure that the product complies with
our claims. Few air purification products are listed by the FDA, and it is extremely important that we expend the resources necessary
to maintain this listing as a Class II medical device with the FDA.

Seasonality

Our
business is affected by traditional retail seasonality, advertising and promotion programs and general economic trends.

Employees

As
of December 31, 2025, Vystar had one employee.

Corporate
Information

Vystar
Corporation is a Georgia corporation that was incorporated in 2003. Our predecessor company, Vystar LLC, was formed by our founder, Travis
Honeycutt, in February 2000 as a Georgia limited liability company. Our corporate office is located at 365 Shrewsbury Street, Worcester,
Massachusetts 01604. Our website address is www.vystarcorp.com, www.rxair.com and www.vytex.com.

5

The
information contained on, or that can be accessed through, our website is not a part of this Report. We have links on our website to
reports, information statements, and other information that we file electronically with the Securities and Exchange Commission, or SEC,
at the Internet website maintained by the SEC, www.sec.gov. In addition to visiting our website and the SEC’s website, you may
read and copy public reports we file with or furnish to the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington,
D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.